Prospective Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2365-2372
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Table 1 The baseline characteristics of patients
VariablesAll (n = 20)
Age, yr68.6 ± 8.4
Gender, male : female19:1
BMI, kg/m222.2 ± 4.2
ECOG PS, 0:1:18:2
Etiology, HBV:HCV:alcohol:others7:7:3:3
AST, IU/L52.2 ± 38.1
ALT, IU/L45.1 ± 26.3
T.Bil, mg/dL0.7 ± 0.4
Alb, g/dL3.4 ± 0.5
PT, %82.2 ± 15.2
Plt, × 104/μL19.7 ± 6.1
Child–Pugh score, 5:6 points8:12
Median AFP, ng/mL (range)268 (4.5-53000)
Intrahepatic tumor size, cm6.6 ± 6.3
Number of intrahepatic tumors, single : multiple3:17
Portal vein invasion, n (%)9 (45.0)
Extrahepatic metastasis, n (%)15 (75.0)
Previous treatment, n (%)19 (95.0)
Initial dose of lenvatinib, 8:12 mg/d16:4
Table 2 Distribution of changes in time-intensity curve parameters in tumors from day 0 to day 7 for 20 hepatocellular carcinoma patients according to modified Response Evaluation Criteria in Solid Tumors response at 2 mo
Responders (n = 9)
Non-responders (n = 11)
Day 0Day 7Day 0Day 7
Slope1.51 [1.31, 1.68]1.09 [0.84, 1.23]1.52 [1.22, 1.62]1.33 [0.86, 1.71]
P value0.0180.511
TTP10.56 [9.33, 12.13]12.43 [11.94, 13.94]11.02 [8.53, 12.51]11.84 [10.15, 13.82]
P value0.0030.247
AUC266.51 [225.38, 296.67]156.44 [123.05, 178.91]258.14 [191.61, 299.51]229.65 [176.10, 269.50]
P value0.0010.322
Table 3 The performance characteristics of the rate of change of time-intensity curve parameters for the prediction of responders
Slope (95%CI)TTP (95%CI)AUC (95%CI)
AUROC0.818 (0.602-0.944)0.869 (0.728-0.975)0.939 (0.812-0995)
Cut-off value (%)-11.765+9.495-25.714
Sensitivity0.889 (0.540-0.978)0.889 (0.540-0.978)0.896 (0.616-0.989)
Specificity0.545 (0.304-0.786)0.818 (0.510-0.917)0.909 (0.648-0.995)
PPV0.615 (0.583-0.793)0.800 (0.611-0.907)0.833 (0.727-0.918)
NPV0.857 (0.731-0.922)0.878 (0.741-0.962)0.900 (0.747-0.992)